Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland
Marco Kaufmann, Jens Kuhle, Milo A Puhan, Christian P Kamm, Andrew Chan, Anke Salmen, Jürg Kesselring, Pasquale Calabrese, Claudio Gobbi, Caroline Pot, Nina Steinemann, Stephanie Rodgers, Viktor von Wyl, Swiss Multiple Sclerosis Registry (SMSR), Marco Kaufmann, Jens Kuhle, Milo A Puhan, Christian P Kamm, Andrew Chan, Anke Salmen, Jürg Kesselring, Pasquale Calabrese, Claudio Gobbi, Caroline Pot, Nina Steinemann, Stephanie Rodgers, Viktor von Wyl, Swiss Multiple Sclerosis Registry (SMSR)
Abstract
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis.
Objectives: The objective of this study was to investigate factors associated with extended time to diagnosis and time to disease-modifying treatment initiation in the Swiss Multiple Sclerosis Registry.
Methods: We used retrospective data (diagnoses 1996-2017) of the survey-based Swiss Multiple Sclerosis Registry and fitted logistic regression models (extended time to diagnosis ≥2 years from first symptoms, extended time to disease-modifying treatment initiation ≥1 year from diagnosis) with demographic and a priori defined variables.
Results: Our study, based on 996 persons with multiple sclerosis, suggests that 40% had an extended time to diagnosis, and extended time to disease-modifying treatment initiation was seen in 23%. Factors associated with extended time to diagnosis were primary progressive multiple sclerosis (odds ratio (OR) 5.09 (3.12-8.49)), diagnosis setting outside of hospital (neurologist (private practice) OR 1.54 (1.16-2.05)) and more uncommon first symptoms (per additional symptom OR 1.17 (1.06-1.30)). Older age at onset (per additional 5 years OR 0.84 (0.78-0.90)) and gait problems (OR 0.65 (0.47-0.89)) or paresthesia (OR 0.72 (0.54-0.95)) as first symptoms were associated with shorter time to diagnosis. Extended time to disease-modifying treatment initiation was associated with older age at diagnosis (per additional 5 years OR 1.18 (1.09-1.29)). In more recent years, time to diagnosis and time to disease-modifying treatment initiation tended to be shorter.
Conclusions: Even in recent periods, substantial and partially systematic variation regarding time to diagnosis and time to disease-modifying treatment initiation remains. With the emerging paradigm of early treatment, the residual variation should be monitored carefully.
Keywords: Registries; age of onset; disease-modifying treatment; logistic models; retrospective studies; time to diagnosis.
Figures
References
- Thompson AJ, Banwell BL, Barkhof al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–73S. DOI: 10.1016/S1474-4422(17)30470-2.
- Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Heal Drug Benefits 2015; 8: 448–453.
- Straus Farber R, Harel A, Lublin F. Novel agents for relapsing forms of multiple sclerosis. Annu Rev Med 2016; 67: 309–321.
- Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14: 859–873.
- Stahnke AM, Holt KM. Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. Ann Pharmacother 2018; 52: 473–483. DOI: 10.1177/1060028017747635.
- Clanet MC, Wolinsky JS, Ashton RJ, et al. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler J 2014; 20: 1306–1311.
- Ng P, Murray S, Hayes SM. Clinical decision-making in multiple sclerosis: challenges reported internationally with emerging treatment complexity. Mult Scler Relat Disord 2015; 4: 320–328.
- Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9: 5–48.
- Gold R, Wolinsky JS, Amato MP, et al. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 351–367.
- Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 2016; 389: 1347–56. DOI: 10.1016/S0140-6736(16)32388-1.
- Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler J 2017; 23: 1233–1240.
- Marrie RA, Cutter G, Tyry T, et al. Changes in the ascertainment of multiple sclerosis. Neurology 2005; 65: 1066–1070.
- Fernández O, Fernández V, Arbizu T, et al. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol 2010; 257: 1500–1507.
- Kingwell E, Leung AL, Roger E, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010; 292: 57–62.
- The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. Neurology 1993; 43: 655.
- Swissmedic. Zugelassene Präparate/Médicaments autorisés (2017, accessed 3 January 2018).
- Steinemann N, Kuhle J, Calabrese al. The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. BMC Neurol 2018; 18: 11. DOI: 10.1186/s12883-018-1118-0.
- Puhan MA, Steinemann N, Kamm al. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. Swiss Med Wkly 2018; 148: w14623. DOI: 10.4414/smw.2018.14623.
- Flachenecker P, Zettl UK, Götze U, et al. MS-Register in Deutschland – Design und erste Ergebnisse der Pilotphase. Nervenarzt 2005; 76: 967–975.
- Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716–723.
- Lindquist MA. Variable Selection (2011, accessed 3 January 2018).
- Faraway J. Variable Selection. In Practical Regression and Anova using R, p. 124–133.
- R Development Core Team. R: A language and environment for statistical computing R Foundation for Statistical Computing. (2017, accessed 3 January 2018).
- Eurostat. Healthcare activities statistics – consultations (2017, accessed 4 January 2018).
- Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 2017; 8: 577.
- Arroyo R, Sempere AP, Ruiz-Beato al. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open 2017; 7: e014433. DOI: 10.1136/bmjopen-2016-014433.
- Lynd LD, Traboulsee A, Marra CA, et al. Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best–worst scaling study. Ther Adv Neurol Disord 2016; 9: 287–296.
- Garcia-Dominguez JM, Muñoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adher 2016; 10: 1945–1956.
- Matell H, Lycke J, Svenningsson A, et al. Age-dependent effects on the treatment response of natalizumab in MS patients. Mult Scler J 2015; 21: 48–56.
- Calabrese P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results from Switzerland. Mult Scler J 2017; 23: 192–203.
- Jones KH, Ford DV, Jones PA, et al. How people with multiple sclerosis rate their quality of life: an EQ-5D survey via the UK MS Register. PLoS One 2013; 8: e65640. .
- Federation Multiple Sclerosis International. Atlas of MS (2013, accessed 4 January 2018).
- Middleton RM, Rodgers W.J, Chataway J, et al. Validating the portal population of the United Kingdom Multiple Sclerosis Register. Mult Scler Relat Disord 2018; 24: 3–10.
Source: PubMed